Table 2 |
||||||||||
| Different expression of c-Jun, N-ras, Caspase9 and p73 in different clinical stages of thymoma n (%) | ||||||||||
| Stage I N = 21 | Stage II N = 20 | Stage III N = 15 | Stage IV N = 4 | Total N = 60 | Pa | Pb | Pc | Pd | ||
| C-Jun | + | 6 (28.6) | 4 (20.0) | 8 (53.3) | 4 (100.0) | 22 (36.7) | 0.009 | 0.004 | 0.523 | 0.245 |
| N-ras | + | 3 (14.3) | 3 (15.0) | 6 (40.0) | 0 (0) | 12 (20.0) | 0.184 | |||
| Caspase9 | + | 8 (38.1) | 11 (55.0) | 8 (53.3) | 3 (75.0) | 30 (50.0) | 0.482 | |||
| p73 | + | 6 (28.6) | 10 (50.0) | 9 (60.0) | 3 (75.0) | 28(46.6) | 0.089 | |||
Pa: Two-sided Fisher’s exact test for distributions between different stages of TETs.
Pb: Two-sided Fisher’s exact test for distributions between stage III + IV and stage I + II of TETs.
Pc: Two-sided Fisher’s exact test for distributions between stage I and stage II of TETs.
Pd: Two-sided Fisher’s exact test for distributions between stage III and stage IV of TETs.
Ma et al. Diagnostic Pathology 2012 7:120 doi:10.1186/1746-1596-7-120
